Sign Up
Stories
ADMA Biologics CFO Transition Revealed
Share
Adial Pharmaceuticals Boosts AD04 Develo...
Adial Pharmaceuticals Boosts Funds for A...
Adial Pharmaceuticals Funds AD04 Develop...
ADMA Biologics CFO Transition Announceme...
ADOCIA Files 2023 Registration Document
Adex Mining Secures $1M Loan
Overview
API
ADMA Biologics, Inc. announced CFO transition with Brian Lenz moving to consulting role while Adam Grossman takes over as Interim CFO. The company is a biopharmaceutical firm specializing in manufacturing biologics for immunodeficient patients and those vulnerable to infectious diseases.
Ask a question
Could this leadership change signal broader shifts or innovations within the biopharmaceutical industry?
How might this CFO transition impact the financial strategies and growth prospects of ADMA Biologics?
What qualities will ADMA Biologics seek in the search for a permanent CFO replacement?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage